Zealand Pharma A/S (Zealand Pharma A/S) Cash-to-Debt : 13.70 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zealand Pharma A/S's cash to debt ratio for the quarter that ended in Dec. 2023 was 13.70.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zealand Pharma A/S could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Zealand Pharma A/S's Cash-to-Debt or its related term are showing as below:

ZLDPF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.97 Med: 3.77 Max: No Debt
Current: 13.7

During the past 13 years, Zealand Pharma A/S's highest Cash to Debt Ratio was No Debt. The lowest was 0.97. And the median was 3.77.

ZLDPF's Cash-to-Debt is ranked better than
59.88% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs ZLDPF: 13.70

Zealand Pharma A/S Cash-to-Debt Historical Data

The historical data trend for Zealand Pharma A/S's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zealand Pharma A/S Cash-to-Debt Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

15.38

9.67

1.81

2.66

13.70

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.66	1.95	14.48	13.63	13.70

Competitive Comparison of Zealand Pharma A/S's Cash-to-Debt

For the Biotechnology subindustry, Zealand Pharma A/S's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cash-to-Debt falls into.

Zealand Pharma A/S Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zealand Pharma A/S's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	238.933	/	(2.437	+	15.008)
	=	13.70

Zealand Pharma A/S's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	238.933	/	(2.437	+	15.008)
	=	13.70

Zealand Pharma A/S (OTCPK:ZLDPF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zealand Pharma A/S Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.